BPMC - Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance

• Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.68 misses by $0.45 .
• Revenue of $36.5M (+33.7% Y/Y) misses by $1.11M .
• As of June 30, 2022, cash, cash equivalents and investments were $947.2M, as compared to $1,034.6M as of December 31, 2021.
• Blueprint Medicines anticipates approximately $180M to $200M in total revenues in 2022 vs. consensus of $195.44M, including approximately $115M to $130M in AYVAKIT net product revenues.
• The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.

For further details see: